VERACYTE, INC.
ARK ETFs sold 16,422 Alphabet (GOOGL) shares for $5.8M, bought 359,612 Rocket Lab (RKLB) shares for $25.1M. Also reduced Twist Bioscience (TWST) and 10X Genomics (TXG) positions, while increasing stakes in Scribe Therapeutics (SCTX), Veracyte (VCYT), and Beam Therapeutics (BEAM).
ARK Genomic Revolution ETF (ARKG) managed by Cathie Wood bought shares of Ionis Pharmaceuticals (IONS), Veracyte (VCYT), Beam Therapeutics (BEAM), and Scribe Therapeutics (SCTX), while selling 10x Genomics (TXG). Other ETFs like GNOM, PBE, FBT, and XBI also hold these biotech companies, offering varied exposure to genomics and biotechnology sectors.
ARK Invest increased stakes in Ionis Pharmaceuticals (IONS), Veracyte (VCYT), Scribe Therapeutics (SCTX), and Beam Therapeutics (BEAM), while reducing exposure to 10x Genomics (TXG). The ETF bought shares worth millions in each biotech firm, with IONS, SCTX, and BEAM seeing pre-market gains, while VCYT declined. ARK also invested $37 million in Meta Platforms (META) across three ETFs, following a surge in Meta's shares.
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning VCYT (VERACYTE, INC.). Coverage has skewed bullish: 3 bullish, 2 neutral, and 0 bearish.
Recent VCYT coverage spans market movers, financial news and earnings.
In the last 30 days, VCYT insiders filed 9 SEC Form 4 transactions — no purchases and 9 sales ($1.3M). The most active reporter was McGuire Annie, EVP, General Counsel, with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Small positive indication for Veracyte.
Veracyte receives fresh capital from a high‑profile fund.
Acquisition plus fund buying could stabilize the stock after a slight pre‑market dip.
The deal expands Veracyte's urology diagnostics, potentially boosting revenue and market position.
New stake could add short‑term buying interest.
AlphAI scores every news story that mentions VCYT with an AI model for sentiment and relevance, and aggregates insider trades from VERACYTE, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
ARK ETFs sold 16,422 Alphabet (GOOGL) shares for $5.8M, bought 359,612 Rocket Lab (RKLB) shares for $25.1M. Also reduced Twist Bioscience (TWST) and 10X Genomics (TXG) positions, while increasing stakes in Scribe Therapeutics (SCTX), Veracyte (VCYT), and Beam Therapeutics (BEAM).
2 min readARK Genomic Revolution ETF (ARKG) managed by Cathie Wood bought shares of Ionis Pharmaceuticals (IONS), Veracyte (VCYT), Beam Therapeutics (BEAM), and Scribe Therapeutics (SCTX), while selling 10x Genomics (TXG). Other ETFs like GNOM, PBE, FBT, and XBI also hold these biotech companies, offering varied exposure to genomics and biotechnology sectors.
2 min readARK Invest increased stakes in Ionis Pharmaceuticals (IONS), Veracyte (VCYT), Scribe Therapeutics (SCTX), and Beam Therapeutics (BEAM), while reducing exposure to 10x Genomics (TXG). The ETF bought shares worth millions in each biotech firm, with IONS, SCTX, and BEAM seeing pre-market gains, while VCYT declined. ARK also invested $37 million in Meta Platforms (META) across three ETFs, following a surge in Meta's shares.
2 min readVERACYTE, INC. (VCYT) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform Acquisition positions Veracyte to deliver powerful genomic insights from urine, tissue, and blood to help guide bladder cancer care across the
2 min readARK Invest, led by Cathie Wood, bought shares of Robinhood Markets (HOOD) and the 3iQ Solana Staking ETF (SOLQ.U) amid a market selloff triggered by strong U.S. jobs data, raising expectations of a Fed rate hike. ARKG added 28,589 HOOD shares ($3.49M) and 3,392 SOLQ.U shares ($28,120). The Dow, S&P 500, and Nasdaq fell 0.51%, 0.38%, and 0.29% respectively.
2 min readFebbo Phillip G. (Chief Scientific & Med Officer) sold 13,110 shares of VERACYTE, INC. (VCYT) at an average of $43.05 ($42.89–$43.66, $0.56M total) across 2 trades on 2026-09-04 under a Rule 10b5-1 trading plan.
1 min readVERACYTE, INC. (VCYT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Veracyte Announces Second Quarter 2026 Financial Results Grew total revenue to $150.3 million and testing revenue to $145.7 million, representing increases of 15% and 19% year-over-year, respectively Conference call and webcast today at 4:30 p.m. ET SOUTH SAN FRANCIS
6 min readMeridian Small Cap Growth Fund’s Q2 2026 investor letter cited Veracyte, Inc. (NASDAQ:VCYT) after the company’s earnings beat and an upward revision to full-year guidance. The article notes VCYT closed at $55.71 on July 29, 2026, with Q1 2026 revenue of $139.1 million (21% YoY) and mentions Decipher and Afirma performance plus upcoming launches.
4 min readArk Invest, led by Cathie Wood, sold shares from its ARKK ETF during a market rally tied to a U.S.-Iran peace agreement. Reported trades include selling 66,259 Palantir shares (~$8.9M at $134.71), 6,904 TSM shares (~$3.0M at $441.40), and 46,783 Amazon shares (~$11.5M at $246.02). The article also cites other sales (e.g., 10X Genomics, Veracyte, Shopify).
5 min readVERACYTE, INC. (VCYT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ex1018-k06x10x2026.htm EX-10.1 Document Exhibit 10.1 VERACYTE, INC. 2023 EQUITY INCENTIVE PLAN, AS AMENDED (ADOPTED BY THE BOARD OF DIRECTORS ON APRIL 12, 2023, AS AMENDED JUNE 12, 2024, JUNE 17, 2025 AND JUNE 10, 2026) 1. PURPOSE. The purpose of this Plan is to provide
4 min read
